Los Angeles-based Cedars-Sinai will receive up to $5,054,235 from the federal ARPA-H CATALYST program to develop an AI platform designed to predict drug toxicity before clinical trials begin.
The platform will use AI to analyze “patient avatars” — organ-on-chip systems derived from human stem cells — to forecast how medications may affect human organs over time. The goal is to reduce clinical trial failures caused by adverse drug reactions, which account for more than 30% of trial shutdowns, according to a Jan. 13 news release from the health system.
The AI system is powered by millions of de-identified data points from Cedars-Sinai’s EHRs and incorporates patient-specific factors such as age, comorbidities and medication use to model evolving drug risk.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
